Cargando…

Co-expression of High-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) in the prognosis of esophageal squamous cell carcinoma

Esophageal cancer is a malignant type of cancer with a high mortality rate. The aim of this study is to determine co-expression patterns of High-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) in ESCC (esophageal squamous cell carcinoma) conditions and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lingzhao, Beeraka, Narasimha M., Xie, Linsen, Dong, Li, Liu, Junqi, Wang, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279518/ https://www.ncbi.nlm.nih.gov/pubmed/35829833 http://dx.doi.org/10.1007/s12672-022-00527-9

Ejemplares similares

Serum levels of high mobility group box‐1 protein (HMGB1) and soluble receptors of advanced glycation end‐products (RAGE) in depressed patients treated with electroconvulsive therapy
por: Abe, Hiromi, et al.
Publicado: (2023)

Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis
por: Sun, Xue-Hui, et al.
Publicado: (2016)

Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
por: Yang, Huan, et al.
Publicado: (2019)

Increased Serum High Mobility Group Box 1 (HMGB1) Concentration and the Altered Expression of HMGB1 and Its Receptor Advanced Glycation Endproducts in Pemphigus
por: Li, Jia-Yi, et al.
Publicado: (2017)

High-Mobility Group Box 1 (HMGB1) Induces Migration of Endothelial Progenitor Cell via Receptor for Advanced Glycation End-Products (RAGE)-Dependent PI3K/Akt/eNOS Signaling Pathway
por: Zhang, Yulong, et al.
Publicado: (2019)

Anti-high-mobility group box-1 (HMGB1) mediates the apoptosis of alveolar epithelial cells (AEC) by receptor of advanced glycation end-products (RAGE)/c-Jun N-terminal kinase (JNK) pathway in the rats of crush injuries
por: Zhang, Bin-Fei, et al.
Publicado: (2022)

The Receptor for Advanced Glycation Endproducts (RAGE) and Its Ligands S100A8/A9 and High Mobility Group Box Protein 1 (HMGB1) Are Key Regulators of Myeloid-Derived Suppressor Cells
por: Ostrand-Rosenberg, Suzanne, et al.
Publicado: (2023)

HMGB1/Advanced Glycation End Products (RAGE) does not aggravate inflammation but promote endogenous neural stem cells differentiation in spinal cord injury
por: Wang, Hongyu, et al.
Publicado: (2017)

The Receptor for Advanced Glycation End Products (RAGE) and the Lung
por: Buckley, Stephen T., et al.
Publicado: (2010)

The Immune Tolerance Role of the HMGB1-RAGE Axis
por: Watanabe, Haruki, et al.
Publicado: (2021)

High mobility group box 1 (HMGB1) quantified by ELISA that dose not cross-react with HMGB2
por: Yakabe, K, et al.
Publicado: (2005)

The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer
por: Süren, Dinç, et al.
Publicado: (2014)

Role of High Mobility Group Box 1 (HMGB1) in SCA17 Pathogenesis
por: Lee, Li-Ching, et al.
Publicado: (2014)

High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll-like receptor 4
por: Wang, Chen, et al.
Publicado: (2015)

HMGB1 Promotes Lymphangiogenesis through the Activation of RAGE on M2 Macrophages in Laryngeal Squamous Cell Carcinoma
por: Su, Caili, et al.
Publicado: (2022)

Role of receptor for advanced glycation end products (RAGE) in liver disease
por: Yamagishi, Sho-ichi, et al.
Publicado: (2015)

Hypoxia and the Receptor for Advanced Glycation End Products (RAGE) Signaling in Cancer
por: Taneja, Sakshi, et al.
Publicado: (2021)

Leptin and advanced glycation end products receptor (RAGE) in tuberculosis patients
por: Lazzari, Tássia Kirchmann, et al.
Publicado: (2021)

The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases
por: Delrue, Charlotte, et al.
Publicado: (2023)

Receptor for advanced glycation end-products (RAGE) mediates phagocytosis in nonprofessional phagocytes
por: Yang, Yan, et al.
Publicado: (2022)

sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells
por: Zhang, Fang, et al.
Publicado: (2017)

The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases
por: Chen, Qingjie, et al.
Publicado: (2016)

Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea
por: Liu, Wenjing, et al.
Publicado: (2023)

Extracellular HMGB1 interacts with RAGE and promotes chemoresistance in acute leukemia cells
por: Lai, Weixin, et al.
Publicado: (2021)

Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases
por: Yue, Qing, et al.
Publicado: (2022)

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
por: Abdulahad, Deena A, et al.
Publicado: (2011)

Role of Glycated High Mobility Group Box-1 in Gastric Cancer
por: Kishi, Shingo, et al.
Publicado: (2021)

The Role of Receptor for Advanced Glycation End Products (RAGE) in the Proliferation of Hepatocellular Carcinoma
por: Yaser, Al-Madhagi, et al.
Publicado: (2012)

The Receptor for Advanced Glycation End Products (RAGE) Contributes to the Progression of Emphysema in Mice
por: Sambamurthy, Nisha, et al.
Publicado: (2015)

The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation
por: Lancefield, Terase F., et al.
Publicado: (2016)

Receptor for the Advanced Glycation End Products (RAGE) Pathway in Adipose Tissue Metabolism
por: Gutowska, Klaudia, et al.
Publicado: (2023)

Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands
por: Yao, Dachun, et al.
Publicado: (2010)

The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway
por: Ren, Liuyang, et al.
Publicado: (2021)

Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases
por: Pilzweger, Christin, et al.
Publicado: (2015)

Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis
por: Szczepanski, Miroslaw J., et al.
Publicado: (2014)

Mechanism of HMGB1–RAGE in Kawasaki disease with coronary artery injury
por: Qian, Biying, et al.
Publicado: (2020)

RAGE and HMGB1 Expression in Orbital Tissue Microenvironment in Graves' Ophthalmopathy
por: Łacheta, Dominika, et al.
Publicado: (2021)

Therapeutic Potential of Targeting the HMGB1/RAGE Axis in Inflammatory Diseases
por: Singh, Harbinder, et al.
Publicado: (2022)

Polymorphisms −374 T/A and −429 T/C of the Receptor for Advanced Glycation End-Products (RAGE) and Serum Levels of RAGE (sRAGE) Are Not Associated with Metabolic Syndrome
por: González-Guerrero, Diana Elizabeth, et al.
Publicado: (2023)

Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes
por: Soro-Paavonen, Aino, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_jkann4uq1fg30504264i1amkgs